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Summary Sublines of a human myeloid leukaemia cell line, KBM-3, with increasing degrees of resistance to
the antileukaemic agent 4'-(9-acridinlylamino) methanesulphon-m-anisidide (m-AMSA) were evaluated for
their response to this drug using a clonogenic assay to measure cell survival and alkaline elution to assess
m-AMSA induced DNA strand breakage. Polyacrylamide gel electrophoresis was used to map the protein
profiles of the various cell lines. The resistant lines were obtained by intermittent exposure of the KBM-3 cells
to the highest tolerated concentration of m-AMSA so that the culture would be repopulated only by the most
resistant subpopulation after each exposure. Two distinct phases were apparent during the development of
resistance. During the first 14 months of intermittent exposure to maximally tolerated concentrations of
m-AMSA, the cells developed low-degree m-AMSA resistance (5-7-fold as compared with the parent line, as
measured by cell survival). This low-degree resistance was characterised by a somewhat suppressed level of
DNA strand breakage and no measurable change in cellular protein levels. Subsequently, a single escalation of
the m-AMSA retreatment concentration resulted in a cell population that was approximately 100-fold
resistant, as assessed by cloning. This rapid phenotypic change temporally coincided with the acquisition of an
almost complete refractoriness to m-AMSA-induced DNA strand breakage and the loss of a cellular 76 kDa
protein. We suggest that the loss of this protein is important for the development of a highly m-AMSA
resistant phenotype.
The emergence of drug resistance during the treatment of
malignant disease continues to be a major reason for
therapeutic failure. Understanding the cellular mechanisms
for the development of drug resistance is therefore of major
importance for the successful circumvention of this problem.
Such mechanistic studies are greatly facilitated by the
availability of continuously growing tumour cell lines with
experimentally induced resistance to different antineoplastic
agents.
Human acute myelogenous leukamia (AML) cell lines such
as HL-60 (Collins et al., 1977; Gallagher et al., 1979) have
been used to generate models of resistance to the
antileukaemic agent 4'-(9-acridinylamino) methanesulphon-
m-anisidide (m-AMSA) (Odaimi et al., 1986; Beran &
Andersson 1987). Our previous studies of HL-60/AMSA
showed that the highly resistant cells had significantly fewer
m-AMSA induced topoisomerase II mediated DNA strand
breaks than the drug sensitive parent line (Bakic et al., 1986).
Since it has not been established whether the observed
decrease in m-AMSA induced DNA strand breakage is a
general mechanism for m-AMSA resistance in human AML
or a phenomenon uniquely associated with the highly resis-
tant HL-60 cell line, we expanded our investigation to a
second human AML cell line, KBM-3. It is also questionable
whether the phenomena observed in highly resistant cell lines
can completely explain the lower degrees of resistance that
are likely to be observed in a clinical situation. We therefore
examined several sublines of KBM-3 with increasing degrees
of resistance to m-AMSA. We used the alkaline elution
technique to measure DNA strand scission in each of these
cell lines after exposure to various concentrations of m-
AMSA and correlated the results with the phenotypic expres-
sion of resistance as measured by clonogenic assay.
In a preliminary study we analysed total cellular proteins
from HL-60, KBM-3 and their respective high-degree m-
AMSA resistant sublines; these initial results suggested the
disappearance of a specific protein band with a molecular
mass of 76 kDa in the highly resistant sublines, although no
temporal relationship between the development of m-AMSA
resistance and the disappearance of the protein was estab-
lished (Kohli et al., 1987). In the present study we have
examined the time course of the loss of this 76 kDa protein
during the acquisition of m-AMSA resistance in KBM-3
cells.
Our results indicate that there are two phases in the cel-
lular development of resistance to m-AMSA in human AML.
The first of these processes results in low-degree resistance
and in a slight but measurable decrease in m-AMSA induced
DNA strand breaks. The subsequent abrupt transition to a
highly resistant phenotype is temporally related to a refrac-
toriness to m-AMSA induced DNA strand scission and the
disappearance of the 76 kDa protein.
Materials and methods
Cell lines
The KBM-3 cell line was established in 1983 from a patient
with AML at The University of Texas M.D. Anderson
Cancer Center. The cells have an immature monocytic
phenotype and are grown in suspension in Iscove's
modification of Dulbecco's minimal essential medium
(IMDM) (GIBCO Laboratories, Grand Island, NY, USA)
supplemented with 10% heat-inactivated fetal calf serum
(FCS) (Irvine Scientific, Santa Ana, CA, USA). Under these
conditions the cells have a doubling time of approximately
23 h and a plating efficiency in soft agar of about 15%. The
m-AMSA resistant sublines were derived over a period of 18
months through intermittent 60 min exposures at 37°C to
gradually escalating concentrations of the drug added to the
suspension cultures. The cells were treated three times at each
concentration level, each treatment being 1-2 weeks apart.
The exact treatment protocol is shown in Figure 1. The
degree of escalation of m-AMSA concentration and the time
interval between treatments was chosen such that only a few
cells (i.e. the most resistant cells in the population) would
survive the treatment and subsequently repopulate the cul-
ture. This protocol should therefore result in the most rapidly
achievable development of resistance and it approximates the
clinical situation where DNA-intercalating agents such as
m-AMSA are used in intermittent high-dose chemotherapy.
The cellular drug tolerance increased slowly over the first 440
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Figure 1 Protocol used for the development of
tant sublines of KBM-3; the cells were intermitt
m-AMSA in gradually escalating concentratior
37'C. The points marked on this curve represeni
ular sublines that were studied in the prese
(@1)KBM-3; (V) KBM-3/AMSA 6.25; (*) KI
(0) KBM-3/AMSA 12.5; (V) KBM-3/AMSAI
AMSA 20.
days and then rapidly over a relatively shorl
(Figure 1).
Before escalation of the m-AMSA conci
cells were preserved in liquid nitrogen, ti
being that of the tolerated drug concentratio
cryopreservation. These preserved cells also
ups against losing the cell line since the escal,
concentration of m-AMSA was specifically ch
to the limit of tolerance, and indeed on ra'
surviving cells could be recovered.
The cells used in this study were designa
AMSA 6.25, KBM-3/AMSA 10, KBM-3/AM
3/AMSA 15, and KBM-3/AMSA 20. The
refers to the drug concentration in JLm unit
ment at 370C) that was necessary to inhibit
proliferation of the cells in suspension at theii
of acquired resistance. This value therefore
crude estimate of the level of resistance;
estimate of resistance was determined from
the cells in a clonogenic assay, as descr,
preparation for cloning and elution experii
were thawed and passaged twice for 7-10
with 10% FCS.
rn-AMSA treatment conditions
Leukaemic cells in e'arly log-phase at a den
ml -' were exposed for 1 h at 370C to a serie:
m-AMSA in phosphate-buffered saline (I
enriched with glucose, calcium, magnesium
Cells incubated in drug-free enriched PBS ser
After incubation, the cells were washed twice
followed by a 10 min centrifugation at 200g.
resuspended in IMDM and used for in vii
alkaline elution studies.
In vitro cloning
Control and m-AMSA treated cells were pla,
of 5 x 10' cells ml-' and cultured in 35mm
IMDM supplemented with 20% FCS and
viscous support. After incubation for 8 dap
humidified atmosphere of 5% CO2 12% 02
nitrogen to 100%, colonies (clones with mor
were counted using an inverted phase contr
The surviving fraction at each drug conceni
culated by comparing the number of colonie
drug exposure to the colony growth of cel
drug-free enriched PBS. Survival curves w
IC50 (the drug concentration that inhibits 50% of colony
formation) values were calculated, and the resistance index
was determined; the resistance index was defined as the ICso
of the resistant line divided by the ICm of the parent KBM-3
cell line.
Alkaline elution
DNA strand breaks were estimated using the alkaline elution
methodology developed by Kohn and co-workers (Kohn,
7 1979, Kohn et al., 1981) with some modifications. Briefly,
cells in early exponential growth phase were labelled over-
night with methyl '4C-thymidine (25 nCiml-') (Amersham
International, Amersham, UK) and then chased for 6 h in
-, , IMDM supplemented with 10% FCS. After m-AMSA treat-
400 500 ment, 9 x 105 cells were gently deposited on to a 25 mm
diameter 2tim pore polycarbonate membrane (Nuclepore,
f m-AMSA resis- Pleasanton, CA, USA) and then rinsed twice with ice-cold
tently exposed to PBS containing 5 mM EDTA. The cells were lysed with 10 ml
ns for 60 min at of sodium dodecyl sulphate (SDS) (Fisher Scientific, Fair
I only the partic- Lawn, NJ, USA) lysis solution (25 mM Na4 EDTA/2% SDS,
nt investigation: pH 9.7) containing proteinase K (0.5 mg ml-') (EM
BM-3/AMSA 10; Reagents, Darmstadt, FRG). Proteinase K was included in
15; (0) KBM-3/ the lysis solution in all of these studies since it has previously
been demonstrated that all strand breaks in the KBM-3 and
HL-60 cell lines are protein associated (Bakic et al., 1986).
t period of time The lysis solution was retained in contact with the sample for
30 min at room temperature. The cell lysates were then rinsed
entration, some twice with Sml of 20mM Na4 EDTA (pH 10.3), and the
heir designation DNA was eluted overnight in the dark with 0.1 M tetra-
in at the time of propylammonium hydroxide (10% aqueous solution, RSA
served as back- Chemical Co., Ardsley, NY,. USA)/20 mM H4EDTA/0.1%
ated retreatment SDS (w/v) (pH 12.15) at a constant flow rate of
iosen to be close 0.04mlmin-' to give 10 equal fractions of approximately
re occasions no 3.5ml. The DNA in the resulting fractions and that
recovered from the interior of the membrane holder after
tted as KBM-3/ vigorous flushing with 3 ml of 0.4 M NaOH were measured
ISA 12.5, KBM- by liquid scintillation counting using Liquiscint scintillation
numerical suffix fluid (National Diagnostics, Manville, NJ, USA) in a Tri
ts (60min treat- Carb 4530 scintillation counter (Packard Instruments,
appreciably the Laguna Hills, CA, USA). Any DNA remaining on the mem-
r particular level branes was recovered by heating for I h at 60°C in I M HCI
provides a very (0.4ml) followed by the addition of 0.4 M NaOH (2.5 ml) for
a more precise 30 min at room temperature and was again assayed by liquid
the survival of scintillation counting.
^ibed below. In Strand scission factors (SSFs) were calculated from the
ments, the cells resulting elution profiles as the absolute value of the log of
days in IMDM the ratio of the percentage of DNA retained on the memb-
rane for the m-AMSA treated sample (after an eluted volume
of 21.0 ml) to the percentage of DNA retained for the unt-
reated control sample (again after an eluted volume of
21.0 ml). These SSF values were then expressed as Gray-
ity of 106 cells equivalents of X-ray induced DNA single-strand breaks by
s of dilutions of using a calibration curve for SSF versus X-ray dose; this
PBS), pH 7.2, calibration curve was derived from an accumulation of data
and 5% FCS. obtained for KBM-3 parent cells that were irradiated on ice
rved as controls. with 250 kVp X-rays (General Electric Maximar Unit, dose
in ice-cold PBS rate 3.3 Gy min-') and analysed for SSB induction by
They were then alkaline elution on the same day as the experiments with
tro cloning and m-AMSA-treated cells. All data are the average of at least
three separate experiments.
Protein analysis
ited at a density Exponentially growing cells were collected by centrifugation,
iPetri dishes in washed with PBS, and lysed in 0.5% Nonidet P-40/0.25 M
0.3% agar as sucrose in 10mM Tris/HCI (pH 7.2) buffer containing pro-
ys at 37°C in a tease inhibitors (10 mM sodium fluoride, 0.5 mM
2 balanced with phenylmethylsulphonyl fluoride, 5 Agml1' leupeptin,
re than 50 cells) 5 gml-' aprotinin, 1 mM N-ethyl-maleimide, and 0.25 mM
rast microscope. p-hydroxymercuribenzoate) (all from Sigma Chemical, St
tration was cal- Louis, MO, USA). The Nonidet P-40 lysates were cent-
-s growing after rifuged at 14,000 g for 1 min in an Eppendorff microcent-
[ls incubated in rifuge. The supernatant was subsequently subjected to
ere constructed, polyarcrylamide gel electrophoresis (PAGE) (Laemmli, 1970;m-AMSA RESISTANCE IN HUMAN LEUKAEMIA 53
O'Farrel & O'Farrel, 1977), using a Bio-Rad Protean II gel
electrophoresis apparatus (Bio-Rad Inc., Richmond, CA,
USA). Proteins were visualised by staining with Coomassie
brilliant blue, followed by destaining.
Results
The resistant phenotypes in the KBM-3 cell lines were
developed through intermittent exposure to maximally
tolerated concentrations of m-AMSA. Sublines from the
specific time-points indicated on the curve in Figure 1 were
analysed for their response to m-AMSA by alkaline elution
and cloning and for their protein content by PAGE.
The results of the survival studies on KBM-3 and its
resistant sublines after a 60 min exposure to various concent-
rations of m-AMSA are shown in Figure 2. The colony
forming ability of all cell lines decreased progressively upon
exposure to increasing concentrations of m-AMSA. The IC50
values showed a 7-fold increase from the parent KBM-3 line
up to the KBM-3/AMSA 10 subline, at which point a pro-
nounced shift was observed, reflected by the dramatic in-
crease in the resistance index for the KBM-3/AMSA 12.5,
KBM-3/AMSA 15, and KBM-3/AMSA 20 sublines (Table
I). In fact, the marked increase in resistance index between
KBM-3/AMSA 10 and KBM-3/AMSA 12.5 occurred follow-
ing a single escalation of the m-AMSA retreatment concent-
ration.
We used the sensitive alkaline elution method to compare
the level of DNA strand break induction in the KBM-3 cell
line and its m-AMSA-resistant sublines, since previous
studies had shown that the highly resistant HL-60/AMSA
phenotype exhibited a markedly reduced level of m-AMSA
induced DNA strand breakage (Bakic et al., 1986). The
compiled dose-response curves for the parent KBM-3 line
and for four sublines with increasing degrees of resistance to
m-AMSA are displayed in Figure 3. The two low-degree
resistance sublines, KBM-3/AMSA 6.25 and KBM-3/AMSA
10, had slightly depressed levels of DNA strand breaks com-
pared with the parent line. In these two sublines, and in the
parent line, the maximum level of DNA breakage was
achieved with an m-AMSA concentration of about 0.5 ELM. A
dramatic change in DNA breakage frequency was observed
between the KBM-3/AMSA 10 and KBM-3/AMSA 12.5 sub-
lines; the highly resistant phenotype, exemplified by KBM-3
AMSA 12.5, KBM-3/AMSA 15 and KBM-3/AMSA 20,
manifested a complete absence of m-AMSA induced DNA
strand breaks over this same range ofdrug concentration (i.e.
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Figure 2 In vitro survival of sensitive KBM-3 cells, and KBM-3
sublines with increasing m-AMSA resistance, as a function of the
concentration of m-AMSA (60 min incubation at 37C): (0)
KBM-3; (V) KBM-3/AMSA 6.25; (*) KBM-3/AMSA 10; (0)
KBM-3/AMSA 12.5; (V) KBM-3/AMSA 15; (0) KBM-3/
ASMA 20. Points, mean of two independent experiments in
which the cells at each drug concentration were plated in trip-
licate. Bars, s.d.
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Figure 3 Effect of increasing concentrations of m-AMSA on the
level of protein-associated DNA strand breaks detected in KBM-
3 sublines with varying resistance to the drug: (0) KBM-3; (V)
KBM-3/AMSA 6.25; (*) KBM-3/AMSA 10; (0) KBM-3/
AMSA 12.5; (V) KBM-3/AMSA 15. KBM-3/AMSA 20 cells
were identical to KBM-3/AMSA 15 but are not shown for
clarity. The drug exposures were for 60 min at 37°C in all cases.
Points, mean of three independent experiments. Bars, s.e.
up to 0.5JLM). When the drug concentrations were raised to
the same range as the IC50 values for these high-degree
resistance lines (i.e. up to 50gM), some concentration-
dependent strand breakage was observed, but this effect was
much less pronounced than for the parent or low-degree
resistance lines exposed to 0.5 ylM drug (i.e. concentrations .
their IC50).
Figure 4 shows a representative set of the elution profiles
used to generate the data in Figure 3. The elution profiles of
the KBM-3/AMSA 10 subline and of the KBM-3/AMSA
12.5 subline (which was developed from KBM-3/AMSA 10
cells following a single escalation of the m-AMSA retreat-
ment concentration) clearly illustrate the pronounced transi-
tion in susceptibility to the DNA-damaging effects of m-
AMSA that occurred between these particular degrees of
resistance.
The results of PAGE analysis for cytoplasmic protein con-
tent are shown in Figure 5. The most obvious change was the
loss of a 76 kDa protein band, which disappeared from the
cells at the same point at which high-degree resistance was
observed with alkaline elution and cloning, i.e. at the transi-
tion from the KBM-3/AMSA 10 to the KBM-3/AMSA 12.5
subline. Other minor alterations in the protein profiles could
be discerned, although these changes were somewhat variable
and were impossible to quantitate in a one-dimensional
system.
Discussion
The introduction of m-AMSA into clinical trials in 1978
provided a therapeutic alternative for anthracycline-resistant
AML, producing complete remissions in about 25-30% of
the patients (Legha et al., 1980, 1982). In addition, m-AMSA
in combination with l-B-D-arabinofuranosylcytosine (Ara-C)
produced complete remissions in 70-75% of previously un-
treated patients with AML (Keating et al., 1987). Unfor-
tunately, these figures have not been translated into a sub-
stantial prolongation of remissions or an increased cure rate.
When the leukaemia recurs, drug resistance continues to be a
major clinical obstacle.
Studies of the mechanism of m-AMSA cytotoxicity have54 W.L. SKINNER et al.
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Figure 5 SDS/polyacrylamide gel electrophoresis patterns of cel-
lular proteins extracted from KBM-3, KBM-3/AMSA 6.25,
KBM-3/AMSA 10, KBM-3/AMSA 12.5 and KBM-3/AMSA 15.
The 76 kDa protein is marked with an arrow. The pattern for
KBM-3/AMSA 20 was identical to that for KBM-3/AMSA 15,
but has been omitted for clarity.
Table I IC50 values and resistance indices of KBM-3 cell lines with
various degrees of resistance to m-AMSA
Cell line IC50 value (gM) Resistance index'
KBM-3 0.4 1.0
KBM-3/AMSA 6.25 1.8 4.5
KBM-3/AMSA 10 2.8 7.0
KBM-3/AMSA 12.5 38 95
KBM-3/AMSA 15 40 100
KBM-3/AMSA 20 45 112
'Defined as IC50 of resistant line + IC50 of KBM-3.
0.01
KBM-3/AMSA 12.5
0 10 20 30
Volume eluted (ml)
Figure 4 Typical alkaline elution profiles for KBM-3/AMSA 10
(a, *) and KBM-3/AMSA 12.5 (b, 0) cells after exposure to
various concentrations of m-AMSA for 60 min at 37C.
focused on the role of the interaction between the drug and
DNA topoisomerase II in the production of m-AMSA
induced DNA strand breaks. Such studies have indicated an
altered interaction between m-AMSA and DNA
topoisomerase II in human m-AMSA resistant leukaemia
(Bakic et al., 1986; Estey et al., 1987). Such mechanistic
studies, however, have all been carried out with highly resis-
tant leukaemic cells.
The current investigation used a clonogenic assay, alkaline
elution and PAGE to study potentially more clinically
relevant sublines of KBM-3 with various degrees of m-
AMSA resistance. Our data demonstrate two distinct phases
in the development of resistance to m-AMSA in this human
AML line. The first of these phases, corresponding to the
first 440 days of intermittent exposure to maximally tolerated
concentrations of m-AMSA, was characterised by up to 7-
fold increase in the resistance index and a small but
measurable decrease in the efficiency of DNA strand
breakage by m-AMSA (Figures 2 and 3, Table I). The second
phase, characterised by a dramatic increase in resistance
index and a virtual absence of detectable DNA strand
breakage after exposure of the cells to the same range of test
m-AMSA concentrations that produced a high level of strand
breakage in the parent KBM-3 line, occurred between the
KBM-3/AMSA 10 and the KBM-3/AMSA 12.5 sublines over
a short period of time (between days 440 and 480) (Figures 1
and 4). The magnitude of m-AMSA induced DNA strand
breakage observed using alkaline elution therefore
qualitatively paralleled the resistance index obtained from the
cloning data.
Because the design of the experimental protocol for the
development of m-AMSA resistance will result in the elimina-
tion of all sensitive cells from the culture (as a result of the
extremely cytotoxic concentrations of m-AMSA used), the
cells within any given population (e.g. KBM-3/AMSA 10)
appear to have a relatively uniform resistance to the drug, as
indicated by the observations that (i) the elution profiles for
highly damaged DNA from such cells (e.g. Figure 4) were
essentially linear even after more than 95% of the DNA had
been eluted, with no evidence of a resistant tail, and (ii) the
survival curves for lines of low-degree resistance also showed
no evidence of a resistant tail even at surviving fractions <
1% (Figure 2).
PAGE analysis of the KBM-3/AMSA cell lines with in-
creasing degrees of resistance revealed the sudden disap-
pearance of a 76 kDa protein band between the KBM-3/
AMSA 10 and KBM-3/AMSA 12.5 sublines (Figure 5), i.e.
precisely where the transition from low to high-degree resis-
tance occurred. The temporal correlation between the
development of the high-degree resistance phenotype and the
altered levels of this protein suggests that these two events
may be related.
There are several possible explanations for these observa-
tions. First, the early development of low-degree resistance
may represent either a gradual cellular adaptation to the
stress of intermittent drug exposure or a single event occurr-
ing at some time during this period. It is not possible at
present to discriminate between these two alternatives,
although the fact that the maximally tolerated m-AMSA
concentration did increase progressively with time (Figure 1)
favours the former explanation. The more rapid late phase,
during which the high-degree resistance phenotype developed
concomitantly with a decrease in m-AMSA induced DNA
single-strand breaks and the disappearance of the 76kDa
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protein, may be a result of a separate genetic mutation.
Alternatively, the observed two phases in the development of
m-AMSA resistance may have a common underlying muta-
tional event. The observed development of high-degree resis-
tance at approximately 440 days could result from overex-
pression or amplification of this mutated gene, causing a
suppression of the 76 kDa protein. In this case, both low and
high-degree m-AMSA resistance would be stable phenotypic
changes. The level of the 76 kDa protein may indeed already
be decreased in the cells with low-degree m-AMSA resistance.
However, the sensitivity of our PAGE procedure did not
allow the resolution of possible minor changes in 76 kDa
protein levels; only the major change concomitant with the
cellular transition to a high-degree resistance phenotype
could be detected with certainty.
The underlying mechanism(s) of the observed phenomena
are therefore at present unknown. That a mutational event is
involved at some point is supported by the observation that
the HL-60/AMSA (Beran & Andersson, 1987) and KBM-3/
AMSA high-degree resistance phenotypes (unpublished data)
are extremely stable, with little or no reversion to an
m-AMSA sensitive phenotype on prolonged culturing with-
out further exposure to the drug. The data suggest a strong
temporal correlation between the development of a stable
high-degree resistance phenotype, acquisition of refrac-
toriness to m-AMSA induced DNA-strand breakage, and the
loss of the 76 kDa protein, implying a possible role for this
protein in the cytotoxic activity of m-AMSA. Studies are
under way in our laboratory on the nature and function(s) of
the protein and the (genetic ?) event(s) underlying its disap-
pearance from leukaemia cells that become highly m-AMSA
resistant. The possibility of separate mechanisms for high-
degree as opposed to low-degree resistance to the drug, which
may be clinically more relevant, is being considered. Studies
with clonal populations - e.g. an examination of strand
breakage and 76 kDa protein levels in subclones of the
KBM-3/AMSA 10 subline - will ultimately clarify many of
these questions, as will studies of the stability of the resis-
tance in each of these sublines and their subclones. Clearly, a
complete definition of the mechanisms of m-AMSA resis-
tance in AML cells await the outcome of such studies.
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